Want to see IN:FISCHER full AI Analyst Report?
Top Page
Fischer Medical Ventures Ltd
(FISCHER)
Select Model
Select Model
Rating:45Neutral
Price Target:
₹26.00
▼(-40.46% Downside)
Action:Reiterated
Date:10/27/26
The score is held back primarily by weak financial quality despite strong FY2026 revenue and margin gains, as heavy and persistent negative free cash flow raises sustainability and funding risk. Technicals add further pressure with a pronounced downtrend and negative momentum, though oversold readings modestly temper the downside view. Valuation is mixed: a high P/E is a headwind, partially offset by an unusually high dividend yield.
Positive Factors
Revenue Growth
The sharp FY2026 revenue increase demonstrates a substantial expansion in reported business scale. If the higher level is sustained, it can improve operating leverage, support investment in the company’s medical focus, and provide a stronger base for future earnings generation.
Negative Factors
Persistent Cash Burn
Deeply negative operating and free cash flow despite reported accounting profitability is a major durability concern. Continued cash burn can increase reliance on external funding, reduce financial flexibility, and make the recent earnings improvement less valuable unless cash conversion improves materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp FY2026 revenue increase demonstrates a substantial expansion in reported business scale. If the higher level is sustained, it can improve operating leverage, support investment in the company’s medical focus, and provide a stronger base for future earnings generation.
Read all positive factors
Fischer Medical Ventures Ltd (FISCHER) vs. iShares MSCI India ETF (INDA)
Market Cap
₹16.74B
Dividend Yield0.2%
Average Volume (3M)80.86K
Price to Earnings (P/E)55.8
Beta (1Y)0.49
Revenue Growth195.95%
EPS Growth1526.86%
CountryIN
Employees40
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.46
Shares Outstanding654,515,440
10 Day Avg. Volume105,180
30 Day Avg. Volume80,856
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.83
Price to Sales (P/S)8.52
P/FCF Ratio-20.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fischer Medical Ventures Ltd Business Overview & Revenue Model
Company Description
Fischer Medical Ventures Limited, established in 1993 and headquartered in Chennai, India, is a global provider of medical equipment. The company's operations encompass the manufacturing, distribution, leasing, and maintenance of a wide array of m...
Fischer Medical Ventures Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67B | 3.09B | 1.11B | 209.81M | 1.79M | 0.00 |
| Gross Profit | 1.06B | 949.12M | 191.09M | 45.27M | 1.79M | 0.00 |
| EBITDA | 525.56M | 430.83M | 42.41M | 23.61M | 152.00K | -1.89M |
| Net Income | 298.13M | 312.41M | 12.08M | 18.38M | -365.00K | -2.33M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 6.72B | 4.57B | 863.22M | 3.54M | 1.90M |
| Cash, Cash Equivalents and Short-Term Investments | 250.46M | 250.46M | 2.51B | 379.46M | 358.00K | 156.00K |
| Total Debt | 0.00 | 1.07B | 853.72M | 16.77M | 11.43M | 3.89M |
| Total Liabilities | -3.87B | 2.86B | 1.20B | 52.07M | 6.20M | 4.20M |
| Stockholders Equity | 3.87B | 3.85B | 3.38B | 811.14M | -2.66M | -2.29M |
Cash Flow | ||||||
| Free Cash Flow | -778.10M | -1.29B | -927.25M | -78.37M | -1.46M | -1.77M |
| Operating Cash Flow | -694.93M | -1.01B | -867.38M | -73.52M | -1.46M | -1.77M |
| Investing Cash Flow | -985.52M | -86.20M | -1.25B | -313.86M | 1.00K | 0.00 |
| Financing Cash Flow | -404.42M | 167.56M | 3.15B | 370.57M | 1.66M | 1.48M |
Fischer Medical Ventures Ltd Technical Analysis
Negative
43.67
Price Trends
33.42
Negative
35.31
Negative
36.74
Negative
Market Momentum
-2.36
Positive
30.90
Neutral
45.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FISCHER, the sentiment is Negative. The current price of 43.67 is above the 20-day moving average (MA) of 29.94, above the 50-day MA of 33.42, and above the 200-day MA of 36.74, indicating a bearish trend. The MACD of -2.36 indicates Positive momentum. The RSI at 30.90 is Neutral, neither overbought nor oversold. The STOCH value of 45.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FISCHER.
Fischer Medical Ventures Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹20.42B | 48.28 | ― | ― | 47.99% | 117.99% | |
61 Neutral | ₹15.95B | 16.49 | ― | 0.41% | 10.19% | 20.99% | |
61 Neutral | ₹2.96B | 62.85 | ― | 0.38% | 33.66% | 17.10% | |
57 Neutral | ₹16.22B | 28.43 | ― | 0.07% | 40.45% | 174.03% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ₹16.09B | 144.11 | ― | 0.42% | 10.63% | -59.63% | |
45 Neutral | ₹16.74B | 55.78 | ― | 0.20% | 195.95% | 1526.86% |
* General Sector Average
IN:FISCHER
Fischer Medical Ventures Ltd
25.58
-83.35
-76.52%
IN:KRSNAA
Krsnaa Diagnostics Limited
491.55
-302.56
-38.10%
IN:NGLFINE
NGL Fine-Chem Ltd.
2,625.00
1,119.90
74.41%
IN:NURECA
Nureca Ltd.
309.95
21.75
7.55%
IN:SAKAR
Sakar Healthcare Ltd
930.30
575.90
162.50%
IN:TARSONS
Tarsons Products Limited
302.45
13.10
4.53%
Fischer Medical Ventures Ltd Corporate Events
Fischer Medical Ventures to Email FY26 Annual Report and Hold Virtual AGM
Sep 5, 2026
Fischer Medical Ventures Ltd has notified stock exchanges that its Annual Report for the financial year 2025–26 will be dispatched to shareholders electronically, in line with regulatory allowances for digital communication. The company also...
Fischer Medical Ventures Plans One-to-One Virtual Meet With Institutional Investors
Sep 4, 2026
Fischer Medical Ventures Ltd has announced that it will host a one-to-one virtual meeting with institutional investors on Monday, 7 September 2026 at 12:30 p.m. IST. The session will focus on the company’s business and general information al...
Fischer Subsidiary TMIV Imaging Debuts AI-Driven CLARION CT System in India
Aug 28, 2026
Time Medical International Ventures (India) Private Ltd., the wholly owned subsidiary of Fischer Medical Ventures Limited, has launched its next-generation CLARION 64/128-slice AI-driven CT system in India, unveiled at the India Health Expo 2026. ...
Fischer Medical Ventures Opens SEBI-Compliant Window for Physical Share Transfer Re-Lodgement
Aug 11, 2026
Fischer Medical Ventures Ltd has announced that it has published newspaper advertisements in Financial Express and Vishalandra to inform shareholders about a SEBI-mandated special window for re-lodgement of transfer requests for physical shares. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.